The compound targets an important brain receptor and can be used to treat cocaine addiction, for which no effective medications exist, researchers said.
Researchers from the University at Buffalo found the compound, RO5263397, severely blunted a broad range of cocaine addiction behaviours in animals.
"This is the first systematic study to convincingly show that RO5263397 has the potential to treat cocaine addiction," said Jun-Xu Li, senior author and assistant professor of pharmacology and toxicology in the UB School of Medicine and Biomedical Sciences.
TAAR 1 is a novel receptor in the brain that is activated by minute amounts of brain chemicals called trace amines.
Also Read
The compound targets TAAR 1, which is expressed in key drug reward and addiction regions of the brain.
"Because TAAR 1 anatomically and neurochemically is closely related to dopamine - one of the key molecules in the brain that contributes to cocaine addiction - and is thought to be a 'brake' on dopamine activity, drugs that stimulate TAAR 1 may be able to counteract cocaine addiction," Li said.
"When we give the rats RO5263397, they no longer perceive cocaine rewarding, suggesting that the primary effect that drives cocaine addiction in humans has been blunted," said Li.
The compound also markedly blunted cocaine relapse in the animals.
"Cocaine users often stay clean for some time, but may relapse when they re-experience cocaine or hang out in the old cocaine use environments," said Li.
"We found that RO5263397 markedly blocked the effect of cocaine or cocaine-related cues for priming relapse behaviour.
"This compound makes rats less willing to work for cocaine, which led to decreased cocaine use," Li added.